(R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-b]吡啶-4-基苯甲酰胺 | 199433-58-4

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: (R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-b]吡啶-4-基苯甲酰胺
• 中文别名: (R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-B]吡啶-4-基苯甲酰胺；(R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-b]吡啶-4-苯甲酰胺
• 英文名称: (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide
• 英文别名: (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridine-4-yl)-4-(1-aminoethyl)benzamide；(R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)-benzamide；(R)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide；Benzamide, 4-(1-aminoethyl)-N-1H-pyrrolo(2,3-b)pyridin-4-yl-, (R)-；4-[(1R)-1-aminoethyl]-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)benzamide
• CAS: 199433-58-4
• 化学式: C₁₆H₁₆N₄O
• 分子量: 280.329
• InChiKey: JTVBXQAYBIJXRP-SNVBAGLBSA-N

物化性质

• 沸点：
  588.8±50.0 °C(Predicted)
• 密度：
  1.32
• 溶解度：
  DMSO：50 mg/mL（178.37 mM；需要超声波和加热）H2O：< 0.1 mg/mL（不溶）

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.8
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性

Y-33075 是一种有效的 ROCK 抑制剂，源于 Y-27632，但其活性更强，IC50 值为 3.6 nM。

靶点

靶点	IC50 (nM)
ROCK	3.6
PKC	420
CaMKII	810

体外研究

Y-33075（Y-39983）是一种强效的ROCK抑制剂，IC50值为3.6 nM。与Y-27632相比，它对PKC和CaMKII的抑制作用更强。具体而言，Y-27632和Y-33075对PKC的IC50分别为9.0 μM和0.42 μM；对CaMKII的IC50分别为26 μM和0.81 μM。与ROCK相比，Y-27632和Y-33075对PKC的IC50分别是其82和117倍，而对CaMKII则分别是236和225倍。

此外，研究表明，在视网膜节细胞（RGCs）中，使用Y-33075（Y-39983，10 μM）可延长神经突；在兔兔眼房水内，Y-33075（Y-39983，1 μM）能抑制由组胺引起的兔眼睫状动脉段收缩。同时，在高钾溶液中，Y-33075（10 μM）不会影响细胞内钙离子浓度的变化。

体内研究

在兔子眼中，经局部给药后，Y-39983（≥0.01%）可以显著降低眼压（IOP），效果持续2小时。而在猴子中，使用0.05%的Y-39983可使眼压显著下降，在用药后的2至7小时内均有明显效果。另外，100 μM浓度的Y-39983能促进大鼠眼中视网膜节细胞再生轴突的生成。

反应信息

• 作为反应物：
  描述：

  (R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-b]吡啶-4-基苯甲酰胺 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 3.5h， 以2.4 g的产率得到(R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-B]吡啶-4-基苯甲酰胺盐酸盐
  参考文献：
  名称：

  VISUAL FUNCTION DISORDER IMPROVING AGENTS

  摘要：

  公开号：

  EP1378247B1
• 作为产物：
  描述：

  (R)-4-(1-benzyloxycarbonylaminoethyl)benzoic acid chloride 在 盐酸 、 10% palladium hydroxide on charcoal 、 氢气 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 9.5h， 生成 (R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-b]吡啶-4-基苯甲酰胺
  参考文献：
  名称：

  VISUAL FUNCTION DISORDER IMPROVING AGENTS

  摘要：

  公开号：

  EP1378247B1

文献信息

• Nitrogen-containing tricyclic compounds
  申请人：Yamada Rintaro

  公开号：US20060247266A1

  公开（公告）日：2006-11-02

  A novel compound represented by the following formula (1) or a salt thereof [wherein R 1 , R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X 1 . . . X 2 represents —CH(R 2 )—CH(R 3 )—, —CH(R 2 )—CH(R 3 )—CH(R 4 )—, —C(R 2 )═C(R 3 )—, or —C(R 2 )═C(R 3 )—CH(R 4 )—(R 2 , R 3 , and R 4 represent hydrogen atom, or an alkyl group); A 1 , A 11 , A 2 , and A 21 represent hydrogen atom, or an alkyl group; Y represents —CH(A 3 )-, —CH(A 3 )-C(A 4 )(A 41 )-, —CH(A 3 )-C(A 4 )(A 41 )-C(A 5 )(A 51 )-, or a single bond (A 3 , A 4 , A 41 , A 5 , and A 51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or —N(A 6 )(A 61 )(A 6 represents hydrogen atom, or an alkyl group, and A 61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.

  以下式（1）表示的新化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等；X1...X2代表—CH(R2)—CH(R3)—、—CH(R2)—CH(R3)—CH(R4)—、—C(R2)=C(R3)—或—C(R2)=C(R3)—CH(R4)—(R2、R3和R4代表氢原子或烷基)；A1、A11、A2和A21代表氢原子或烷基；Y代表—CH(A3)-、—CH(A3)-C(A4)(A41)-、—CH(A3)-C(A4)(A41)-C(A5)(A51)-或单一键（A3、A4、A41、A5和A51代表氢原子或烷基），Z代表羟基或—N(A6)(A61)(A6代表氢原子或烷基，A61代表氢原子、烷基、取代烷基等)]具有强烈抑制肌球蛋白调节轻链磷酸化的作用。
• Sulfonamide compound
  申请人：Matsubara Koki

  公开号：US20090048223A1

  公开（公告）日：2009-02-19

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an alkylthio group, an amino group, an alkoxycarbonyl group, an acyl group, an acyloxy group, an alkylsulfinyl group, an alkylsulfonyl group, or an aryl group; Y represents a single bond, or —C(R 3 )(R 4 )— (R 3 and R 4 represent hydrogen atom, or an alkyl group, or alkylene groups which combine together to form a saturated hydrocarbon ring group); G 4 represents hydroxyl group (Y is a single group), or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, a saturated heterocyclic group, an alkylsulfonyl group, an acyl group, or an amidino group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  由以下化学式表示的化合物：[A代表含氮饱和环；m表示0到2的整数；n表示1到4的整数；G1代表氢原子、氯原子、羟基、烷氧基或氨基；G2代表卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基、炔基、烷氧基、烷硫基、氨基、烷氧羰基、酰基、乙酰氧基、烷基磺基、烷基磺酰基或芳基；Y代表单键，或-C(R3)(R4)-（R3和R4代表氢原子、烷基或烷烯基，它们结合在一起形成饱和碳氢环基）；G4代表羟基（Y是单个基），或-N(R1)(R2)（R1和R2代表氢原子、烷基、芳基、烯基、炔基、饱和杂环基、烷基磺酰基、酰基或胺基）；G5是A的环构成碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐、或作为前药的衍生物，其强力抑制Rho激酶。
• N-heterocyclic substituted benzamide derivatives with antihypertensive activity
  申请人：Mitsubishi Pharma Corporation

  公开号：EP1195372A1

  公开（公告）日：2002-04-10

  Benzamide compounds of the formula wherein each symbol is as defined in the specification, isomers thereof and pharmaceutically acceptable acid addition salts thereof. Pharmaceutical compositions comprising a therapeutically effective amount of this compound and a pharmaceutically acceptable additive, and therapeutic agents for hypertension, therapeutic agents for angina pectoris, therapeutic agent for asthma, therapeutic agents for renal and peripheral circulatory disturbances and inhibitor of cerebral vasospasm, which comprise this compound. The compound of the present invention has strong smooth muscle relaxing action, and shows hypotensive action and cerebral • coronary vasodilating action like conventional calcium antagonists, as well as long-lasting renal and peripheral circulation improving action. Unlike calcium antagonists, it permits oral administration to suppress vascular contraction caused by various agonists, and is useful as a strong and long-acting agent for prophylaxis and treatment of circulatory diseases in coronary, cerebral, renal and peripheral arteries, as a therapeutic agent for hypertension, angina pectoris, and renal and peripheral circulation disorder, an inhibitor of cerebral vasospasm and the like. Moreover, the compound of the present invention is useful as a therapeutic agent for asthma.

  苯甲酰胺化合物的化学式如规范中所定义的每个符号，其异构体和药学上可接受的酸盐。包括该化合物的治疗有效量和药学上可接受的添加剂的药物组合物，以及治疗高血压、心绞痛、哮喘、肾脏和外周循环障碍以及脑血管痉挛抑制剂的治疗剂，其中包括该化合物。本发明的化合物具有强大的平滑肌松弛作用，表现出类似于传统钙拮抗剂的降压作用和脑冠脉扩张作用，以及持久的肾脏和外周循环改善作用。与钙拮抗剂不同，它允许口服给药以抑制各种激动剂引起的血管收缩，并可用作冠状动脉、脑部、肾脏和外周动脉循环疾病的预防和治疗的强效长效药物，作为治疗高血压、心绞痛、肾脏和外周循环障碍的治疗剂，脑血管痉挛抑制剂等。此外，本发明的化合物还可用作哮喘的治疗剂。
• SULFONAMIDE COMPOUND
  申请人：Yamada Rintaro

  公开号：US20100093789A1

  公开（公告）日：2010-04-15

  A compound represented by the formula (1) [A represents a nitrogen-containing saturated ring; m represents an integer of 0 to 2; n represents an integer of 1 to 4; G 1 represents hydrogen atom, chlorine atom, hydroxyl group, an alkoxy group, or amino group; G 2 represents a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G 3 represents hydrogen atom, a halogen atom, hydroxyl group, cyano group, carboxy group, an alkyl group, an alkenyl group, and the like; G 4 represents hydroxyl group, or —N(R 1 )(R 2 ) (R 1 and R 2 represent hydrogen atom, an alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, or a saturated heterocyclic group); G 5 is a substituent on a ring-constituting carbon atom of A, and represents hydrogen atom, fluorine atom, or an alkyl group] or a salt thereof, or a derivative thereof that is a prodrug, which potently inhibits Rho kinase.

  化合物由以下公式表示(1) [A代表含氮饱和环；m表示0到2的整数；n表示1到4的整数；G1代表氢原子、氯原子、羟基、烷氧基或氨基；G2代表卤原子、羟基、氰基、羧基、烷基、烯基等；G3代表氢原子、卤原子、羟基、氰基、羧基、烷基、烯基等；G4代表羟基，或-N(R1)(R2) (R1和R2代表氢原子、烷基、芳基烷基、烯基、炔基或饱和杂环基)；G5是A的环构成碳原子上的取代基，代表氢原子、氟原子或烷基]或其盐，或其作为前药的衍生物，强力抑制Rho激酶。
• Preventives/remedies for kidney diseases
  申请人：——

  公开号：US20030096843A1

  公开（公告）日：2003-05-22

  A compound having a Rho kinase inhibitory activity, such as (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)-cyclohexane, has a renal interstitial fibrosis inhibitory action in renal interstitial fibrosis model mice and various other actions, and therefore, is useful as an agent for the prophylaxis or treatment of renal diseases.

  具有Rho激酶抑制活性的化合物，例如（+）-trans-4-(1-氨乙基)-1-(4-吡啶基氨甲酰基)-环己烷，对于肾间质纤维化模型小鼠具有肾间质纤维化抑制作用和其他各种作用，因此，可用作预防或治疗肾脏疾病的药物。